Morgan Stanley Arbutus Biopharma Corp Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Morgan Stanley holds 20,960,268 shares of ABUS stock, worth $81.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,960,268
Previous 8,830,297
137.37%
Holding current value
$81.1 Million
Previous $22.8 Million
184.29%
% of portfolio
0.01%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ABUS
# of Institutions
138Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Whitefort Capital Management, LP New York, NY12.9MShares$49.8 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$44.7 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$33.2 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$27.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.31MShares$12.8 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $580M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...